Last reviewed · How we verify
Magnesium sulfate and then Digoxin
Magnesium sulfate and then Digoxin is a Electrolyte supplement and cardiac glycoside combination Small molecule drug developed by Sunnybrook Health Sciences Centre. It is currently in Phase 3 development for Acute arrhythmias with hypomagnesemia, Heart failure with reduced ejection fraction, Atrial fibrillation rate control.
Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction.
Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction. Used for Acute arrhythmias with hypomagnesemia, Heart failure with reduced ejection fraction, Atrial fibrillation rate control.
At a glance
| Generic name | Magnesium sulfate and then Digoxin |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | Electrolyte supplement and cardiac glycoside combination |
| Target | Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Magnesium sulfate acts as an electrolyte replacement and antiarrhythmic agent, stabilizing cardiac membrane potential and reducing ectopic activity. Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing myocardial contractility while also slowing conduction through the AV node via vagomimetic effects. Together, they may be used sequentially to manage acute arrhythmias and heart failure.
Approved indications
- Acute arrhythmias with hypomagnesemia
- Heart failure with reduced ejection fraction
- Atrial fibrillation rate control
Common side effects
- Hypermagnesemia (with magnesium sulfate)
- Digoxin toxicity (nausea, arrhythmias, visual disturbances)
- Hypokalemia exacerbation
- Bradycardia
- AV block
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium sulfate and then Digoxin CI brief — competitive landscape report
- Magnesium sulfate and then Digoxin updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI
Frequently asked questions about Magnesium sulfate and then Digoxin
What is Magnesium sulfate and then Digoxin?
How does Magnesium sulfate and then Digoxin work?
What is Magnesium sulfate and then Digoxin used for?
Who makes Magnesium sulfate and then Digoxin?
What drug class is Magnesium sulfate and then Digoxin in?
What development phase is Magnesium sulfate and then Digoxin in?
What are the side effects of Magnesium sulfate and then Digoxin?
What does Magnesium sulfate and then Digoxin target?
Related
- Drug class: All Electrolyte supplement and cardiac glycoside combination drugs
- Target: All drugs targeting Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)
- Manufacturer: Sunnybrook Health Sciences Centre — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute arrhythmias with hypomagnesemia
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Atrial fibrillation rate control